Dupixent Lawsuit Updates
Lymphoma Risk Claims Emerge as Dupixent Use Expands in Europe
Several studies have reported an increased incidence of lymphoma, a cancer of the lymphatic system, among patients using Dupixent. Individuals diagnosed with lymphoma, along with surviving family members, have filed lawsuits against manufacturers Regeneron and Sanofi, alleging the companies failed to adequately disclose this potential risk. While litigation continues in the United States, European health authorities have expanded approved prescribing guidelines, permitting Dupixent use for patients aged 12 and older with chronic spontaneous urticaria, a condition defined by persistent hives without a known cause.
Dupixent Seeks New Approval Amid Ongoing Cancer Risk Litigation
The medication Dupixent (dupilumab) may soon receive FDA approval for treating allergic fungal rhinosinusitis (AFRS), following study results showing it reduced the need for steroids in half of participants. While the drug is a leading treatment for eczema and related conditions, its use is associated with an elevated risk of T-cell lymphoma, a cancer with symptoms similar to eczema. Patients who developed lymphoma after taking Dupixent are filing lawsuits, alleging the manufacturers failed to provide adequate warnings about this serious potential side effect.
Sanofi's Q3 Earnings Soar on Dupixent Sales Amid Growing Safety Litigation
Sanofi has reported a significant 26.2% increase in its third-quarter earnings, largely driven by sales of its blockbuster drug, Dupixent. While the drug is a major commercial success, its expanding use has correspondingly increased patient exposure to potential severe side effects. Emerging studies and adverse event reports have linked Dupixent to an elevated risk of lymphoma, leading to a growing number of lawsuits filed against Sanofi by patients who allege they developed cancer after taking the medication.
Tennessee Mother Files Wrongful Death Lawsuit Over Dupixent-Linked Lymphoma
A Tennessee mother, Chandra Richardson, has filed a wrongful death lawsuit against Sanofi-Aventis and Regeneron on behalf of her deceased daughter. The complaint alleges that Dupixent injections caused the daughter to develop T-cell lymphoma, which ultimately resulted in her death. The lawsuit seeks compensation for medical expenses, pain and suffering, and emotional injuries, asserting that the manufacturers failed to provide adequate warnings about the potential cancer risk associated with the medication.
About the Dupixent Lawsuit
Once hailed as a breakthrough for conditions like eczema, asthma, and nasal polyps, Dupixent (dupilumab) is now in the spotlight for a darker reason. Dupixent users are coming forward with assertions that the allegedly defective drug caused or worsened their cancers, particularly cutaneous T-cell lymphoma (CTCL). Many of these patients are now filing lawsuits against Sanofi Genzyme and Regeneron Pharmaceuticals in hopes of holding the medication’s producers accountable.
People who used Dupixent or dupilumab and were later diagnosed with an eligible cancer (or experienced worsening of a pre-existing cancer) are encouraged to speak with an experienced attorney to understand their legal options. If you believe you or a loved one may qualify, You can fill out the sign-up form at the top of this page for a no-cost case evaluation.
Understanding Dupixent and Its Medical Uses
Dupixent (generic name dupilumab) is a biologic injectable medication intended to treat a variety of long-term conditions, including:
- Moderate to severe eczema, also known as atopic dermatitis
- Asthma
- Nasal polyps and chronic rhinosinusitis
- Chronic obstructive pulmonary disease (COPD)
- Eosinophilic esophagitis
- Prurigo nodularis
These diseases are all associated with increased inflammation in the body. Dupixent and dupilumab work primarily by blocking proteins involved in the inflammatory process, particularly interleukin-4 (IL-4) and interleukin-13 (IL-13).
The medication was designed as a different method of treatment for these chronic conditions. Unlike many traditional treatments, Dupixent does not require daily doses; instead, the drug is typically injected just once a week, or even less frequently.
This dosing schedule may appeal to patients wishing to spend less time on disease management. However, a wave of lawsuits says this convenience could come at the price of patients’ health.
Who Qualifies For The Dupixent CTCL Lawsuit?
You may be eligible to file a Dupixent dupilumab lawsuit if you meet the following requirements:
- You used Dupixent (or generic dupilumab), and
- You were later diagnosed with Cutaneous T-Cell Lymphoma (CTCL, also known as mycosis fungoides or Sézary syndrome), or
- You experienced a resulting worsening of your pre-existing cancer
You may also qualify if you were diagnosed with another type of T-cell lymphoma or any of the following CTCL subsets:
- Lymphomatoid papulosis
- Subcutaneous panniculitis-like T-cell lymphoma
- Primary cutaneous anaplastic large cell lymphoma
- Extranodal NK/T-cell lymphoma
- Primary cutaneous gamma/delta T-cell lymphoma
Biologic Therapy Risks: Cancer and Dupixent Misdiagnosis
Dupixent was reportedly marketed as a safe and convenient treatment option, but recent litigation claims this might not have been the case. Plaintiffs say the injectable drug is associated with serious health effects, including Cutaneous T-Cell Lymphoma (CTCL), a type of cancer.
Allegedly, Dupixent may increase a patient’s risk of developing CTCL and may also worsen pre-existing cases. Backed by research, these claims reputedly aren’t without merit. Some studies correlate dupilumab use with anywhere from a 300% to 350% greater chance of developing lymphoma. The assertions don’t end there.
CTCL is a rare form of cancer in its own right, which can sometimes lead to a delay in diagnosis. Worse, the cancer misdiagnosis lawsuit states, CTCL symptoms (such as itchy and painful skin rashes or plaques) can overlap with those of atopic dermatitis, one of the main illnesses Dupixent is prescribed to treat.
Because of this symptom overlap, some plaintiffs say neither they nor their doctors were alarmed by their evolving conditions, allegedly preventing a timely CTCL diagnosis. Reportedly, the symptoms instead received an erroneous eczema misdiagnosis, allowing their cancers to go dangerously unnoticed or worsen as they continued using Dupixent.
The Legal Accusations Surrounding Dupixent
For patients suffering from eczema, asthma, and nasal polyps, the search for reliable treatment options can feel like a lifelong uphill battle. Dupixent’s 2017 FDA approval brought hope to those wishing for a different type of therapy.
According to plaintiffs, the medication was marketed by Sanofi and Regeneron to doctors and patients alike as an effective, low-risk drug. Dupixent advertisements reportedly showed happy, clear-skinned people in relaxing social settings, free from any obvious signs of debilitating health problems. The medication is approved for use by patients 6 months old and up, apparently further contributing to its safe appearance.
However, the Dupixent lymphoma lawsuits state that the biologic drug is not as safe as represented by Sanofi and Regeneron. Further, plaintiffs claim that the companies should have reasonably known about Dupixent’s cancer risks yet failed to adequately warn patients and doctors. This purported negligence allegedly contributed to the suffering of patients whose cancers developed or worsened in response to the medication.
As of September 2025, Dupixent has not been recalled and is still being actively marketed by both Big Pharma companies.
How Do I Join The Lawsuit?
No one should have to face cancer for simply attempting to manage their chronic health condition. If you or a loved one were diagnosed with cancer after using Dupixent, you deserve justice.
The best way to seek accountability from pharmaceutical giants like Sanofi and Regeneron is by exercising your legal rights. Working with a qualified Dupixent attorney can give you the greatest chance at a successful lawsuit. If you believe you meet the eligibility requirements, complete the sign-up form on this page to be connected with a lawyer in the OCA network. Your case evaluation is confidential and available at no cost to you.
While considering filing a lawsuit, you may have concerns about the cost of hiring legal counsel. At OCA, we believe your financial situation should have no bearing on your ability to pursue justice. That’s why attorneys in our network typically work on a contingency fee basis, meaning no upfront payment is required. In most cases, a plaintiff would pay a portion of any potential Dupixent settlement or compensation only if their case is successful.
Our team of professionals is here to answer any questions you have about filing a Dupixent lawsuit and is standing by to support you on your legal journey.
Add Comment